Weight loss drugs can halve heart patients’ risk of early death, study finds | Health
Weight loss drugs may reduce half of the risk of heart patients to be hospitalized or premature death, according to the biggest work of the species.
The drug class, known as GLP-1 agonists, offers “dramatic benefits ve to heart patients and significantly reduced the risk of serious illness or premature death.
The discovery at the world’s largest heart conference in Madrid means that millions of heart patients can be given to help them stay away from the hospital and live longer.
Weight loss drugs mimic the glucagon -like peptide (GLP) hormone that makes people feel full and initially developed for diabetes treatment. In recent years, evidence has emerged, which has proved that they may be life -saving under a number of conditions beyond obesity.
The results of the big new research presented at the Annual Conference of the European Association of Cardiology show that weight loss drugs can reduce the risk of heart conditions to hospital or early death.
In the study, US researchers from Mass General Brigham, a non -profit doctor in Boston and a hospital network, analyzed real world data from more than 90,000 heart failure patients with obese and type 2 diabetes. All of them had heart failure with preserved ejection fraction (HFPEF), the most common form of the situation.
The results have shown that the likelihood that Semaglid fields are 42% less likely to die in the hospital or in the hospital or early in compared to a proxy for placebo. In the same study, tirzepathide reduced the risk of hospitalization for heart failure or death by 58%for any reason.
Globally, more than 60 million people have heart failure. Previous studies have suggested that weight loss drugs could improve heart failure symptoms, but their effects on important results such as hospitalization and death have never been evaluated in major populations so far.
The results of the study presented in Madrid were published in Jama, a magazine of the American Medical Association at the same time.
“Despite HFPEF’s widespread morbidity and mortality burden, the current treatment options are limited,” he said.
“Both Semagluid and Tyrzizepathide are well known for its effects on weight loss and blood sugar control, but our study shows that it can offer significant benefits to obesity and type 2 diabetes patients by reducing the results of negative heart failure.
“Our findings show that GLP-1 targeting drugs in the future can provide a very needed treatment option for patients with heart failure.”
Findings contribute to evidence that weight loss drugs can help overcome or prevent heart conditions.
In May, he found that people who receiving a trial, semaglud had a 20% lower heart attack, stroke or death risk due to cardiovascular disease. University College London survey found that Semagluidin provided cardiovascular benefits regardless of the initial weight or the amount of weight they lost.
Dr. Carlos Aguiar, Vice President of the European Cardiology Association, welcomed the world -renowned expert findings on heart failure that is not interested in work.
“This shows that one of these two agents is a benefit of using one of Semaglid or one of the thyrzepathides, to reduce the risk of hospitalization for mortality due to heart failure or all causes.
“In fact, we thought that we would not find a treatment that will work well for a significant part of these patients, and it is a good surprise that it works through weight loss, but probably through other effects that go beyond weight loss, reducing hospitalization and mortality rates in patients with heart failure.”
Aguiar, a cardiology consultant in the hospital Santa Cruz in Carnaxide, Portugal, said that more evidence would be necessary before the use of weight loss medications, but the results of the study were “good news ..
Dr. Sonya Babu-Naran said: “These data contribute to the increasing body of evidence that supports the role of weight loss drugs for patients with both heart failure and obesity to reduce hospital assumptions and death.
“It is very important that patients with appropriate heart failure have the opportunity to be taken into account for these therapies as well as other evidence -based heart failure drugs.”
